Improving quality in prostate cancer care through personalised diagnostic testing – Educational project 2025/2026
Personalised diagnostic tests are essential in tailoring prostate cancer care, leveraging unique molecular features such as gene alterations and protein expression for treatment selection and prognosis. SPCC will host a closed task force on 12th June 2025, followed by a manuscript that will summarise key findings on the role of molecular testing, imaging, and pharmacogenomics in improving disease management and patient outcomes.